Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OMEROS CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

11/09/2020 | 04:10pm EDT

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2020, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2020. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit
Number     Description

99.1         Press release, dated November 9, 2020, pertaining to Omeros
           Corporation's financial results for the three and nine months ended
           September 30, 2020.
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document)

© Edgar Online, source Glimpses

All news about OMEROS CORPORATION
08/09OMEROS : Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/09OMEROS CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
08/09OMEROS CORPORATION : Reports Second Quarter 2021 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter Ended June..
CI
08/03OMEROS CORPORATION : to Announce Second Quarter Financial Results on August 9, 2..
BU
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 112 M - -
Net income 2021 -122 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -8,34x
Yield 2021 -
Capitalization 999 M 999 M -
EV / Sales 2021 11,2x
EV / Sales 2022 6,98x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 15,98 $
Average target price 27,00 $
Spread / Average Target 69,0%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION11.87%999
BIONTECH SE340.60%90 003
GILEAD SCIENCES, INC.22.91%89 434
REGENERON PHARMACEUTICALS34.93%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.33%48 539